Orchard Therapeutics Completes ADS Ratio Change
March 10, 2023 10:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its...
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
March 06, 2023 06:05 ET
|
Orchard Therapeutics (Europe) Limited
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare...
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
March 06, 2023 06:00 ET
|
Orchard Therapeutics (Europe) Limited
Proceeds to accelerate commercialization of Libmeldy and advance the company’s HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025...
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
March 03, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
February 27, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT)...
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
February 24, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite...
Orchard Therapeutics Announces Proposed ADS Ratio Change
February 10, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary...
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
February 08, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic...
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
January 09, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023...
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
January 05, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its...